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Phenylalanine hydroxylation across the kidney in humans. and subsequent oxidation or reversible transamination
Background. Although phenylalanine hydroxylase activity into the corresponding ketoanalog, phenylpyruvic acid
is detectable in in vitro renal tissue preparations, no data on
[2, 3]. Phenylalanine hydroxylation also constitutes ain vivo phenylalanine hydroxylation across the human kidney,
source of circulating tyrosine [1–5]. Thus, the measure-as well as on its possible contribution to whole-body hydroxyla-
tion, currently exist. ment of phenylalanine hydroxylation is an estimate of
Methods. To this aim, we have measured whole-body, renal, both its irreversible catabolism and de novo tyrosine
and splanchnic phenylalanine hydroxylation to tyrosine, as well
production [2–5].as phenylalanine and tyrosine rates of appearance (Ra) and
Disturbances of phenylalanine hydroxylation are pres-disposal (Rd), in postabsorptive subjects by means of renal and
splanchnic arteriovenous catheterization combined with phe- ent in the various forms of phenylketonuria [6, 7]. In
nylalanine and tyrosine isotope infusions. this disease group, plasma (and tissue) phenylalanine
Results. In the kidney, a relevant phenylalanine hydroxyla-
concentrations are increased, whereas tyrosine concen-tion activity was detected (3.51 6 0.97 mmol/min 3 1.73 m2 of
trations may be normal or decreased [6, 7]. In chronicbody surface), whereas it was 2.48 6 1.35 mmol/min 3 1.73 m2
across the splanchnic area. These two sites together accounted renal failure, both tyrosine concentration and net renal
for virtually the entire whole-body phenylalanine hydroxylation. output were found to be decreased and positively corre-
Renal production of tyrosine from phenylalanine hydroxyla-
lated [8], suggesting an important role of this organ intion accounted for approximately 13% of whole-body tyrosine
the production of circulating tyrosine.Ra, whereas renal total tyrosine Ra accounted for approxi-
mately 34% of whole-body tyrosine Ra. In the splanchnic area, The enzyme(s) catalyzing phenylalanine hydroxyla-
these figures were approximately 9 and 40%, respectively. Hy- tion has been located in vitro in both the liver and the
droxylation accounted for approximately 70% of phenylalanine
kidney [2, 3]. However, only limited data are availableRd in the kidney, as opposed to approximately 8% in the
on the site(s) and the extent of organ phenylalaninesplanchnic area.
Conclusions. These data indicate that hydroxylation repre- hydroxylation in humans. Phenylalanine hydroxylation
sents the major route of phenylalanine disposal within the can be estimated in vivo by measuring directly the rate
kidney. The kidney and the splanchnic bed together account
of conversion of isotopically labeled phenylalanine intofor all of the whole-body phenylalanine hydroxylation. These
tyrosine, simultaneously with a tyrosine tracer infusiondata also provide a further explanation for the reduced tyrosine
pools occurring in uremia. [4, 5]. By combining this approach with arteriovenous
catheterization, a significant phenylalanine hydroxylation
has been recently demonstrated across the splanchnic
Phenylalanine is an essential amino acid that is catabo- bed in normal and diabetic subjects [9, 10]. In contrast,
lized by extramuscular tissues [1–3]. Its metabolic path- no direct estimate of renal phenylalanine hydroxylation,
ways include either irreversible hydroxylation to tyrosine as well as of renal phenylalanine and tyrosine kinetics,
is currently available in humans.
Therefore, in this study, we have combined the arterio-Key words: stable isotopes, catheterization, tyrosine, amino acids,
venous difference technique across the kidney anduremia.
splanchnic organs with phenylalanine and tyrosine stable
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METHODS the diagnostic procedure was completed, another cathe-
ter was introduced to allow simultaneous sampling fromSubjects
the renal and the hepatic veins. The position of catheters
Six subjects (4 men and 2 women, aged 39 6 5 years, was ascertained visually through image intensification
all within 110% of their ideal body weight) were studied before each blood withdrawal. The radiation dose ab-
in the postabsorptive state. Their usual diet provided 30 sorbed from fluoroscopy was estimated to be 15 to 20
to 35 kcal/kg/day and 0.9 to 1.0 g protein/kg/day, as mRad. The catheters were kept patent with intermittent
assessed by dietary history and urea excretion. Standard saline flushing. Blood samples were effectively taken
blood chemistry values, glomerular filtration rate, acid after approximately 210 minutes from the start of isotope
base and electrolyte measurements and oral glucose tol- infusion, at the achievement of steady state in both sub-
erance tests were all normal. No subject had any sign strate and isotope concentrations, as well as isotope mole
of gastrointestinal or hepatic disease, congestive heart percentage enrichments (E; data not reported). Three
failure, diabetes mellitus, or other endocrinopathies. Four sets of blood samples were simultaneously drained into
subjects (2 men and 2 women) had arterial hypertension. chilled heparinized syringes from the radial artery, as
Their mean blood pressure was between 125 and 135 well as from the renal, the hepatic, and the femoral veins,
mm Hg. A renal vein catheterization for renin activity for the biochemical determinations, each set being taken
was performed for diagnostic purposes. The final diagno- at approximately 20-minute intervals. Additional sam-
sis was benign arterial hypertension. Two male subjects ples were taken for organ blood flow analyses. The total
had cardiac valvular disease, and a right-sided cardiac duration of the study was therefore approximately 270
catheterization was indicated for the hemodynamic eval- minutes. Arterial blood pressure and electrocardiogram
uation. Before their informed consent was obtained, all were continuously monitored during the study. Room
subjects were informed about the nature, purposes, pro- temperature was maintained between 20 and 228C.
cedures, and possible risks of the study. The study was
part of a larger protocol approved by the Ethical Com- Analytical measurements
mittee of the Department of Internal Medicine at the The whole blood was deproteinized with 20% (wt/vol)
University Hospital of Genova, Genova, Italy, and it perchloric acid as described previously [11]. Phenylala-
complied with the Helsinki declaration. nine and tyrosine concentrations were measured by ion
exchange chromatography (Fisons Instruments Italia SPA,
Isotopes
Milano, Italy) [8] using lithium buffers. The D5-phe, D2-
L-[ring-2H5]-phenylalanine (D5-phe) and L-[2H2]-tyro- tyr, and D4-tyr mole percentage enrichments (E) were
sine (D2-tyr) were purchased from Masstrace (Woburn, determined in the supernatant of deproteinized blood
MA, USA). l-[ring-2H4]-tyrosine (D4-tyr) was obtained by gas chromatography-mass spectrometry (GCMS), as
from Eurisotop (Gif Sur Yvette, France). All isotopes tert-butyl-dimethyl-silyl derivatives and electron impact
were .99% mol percentage enriched and were proven ionization [12]. The monitored fragments were (m/z) 239/
to be sterile and pyrogen free before use. 234 for D5-phe, 468/466 for D2-tyr, and 470/466 for D4-
tyr, respectively. Enrichments were corrected for each
Procedures isotopomer contribution. Blood isotope concentrations
The patients were studied in the recumbent position were calculated by multiplying E times substrate concen-
after an overnight fast. At approximately 8:00 a.m., a trations. All six subjects had the hepatic and femoral
peripheral vein was cannulated with a Teflon catheter vein catheterization performed, whereas five of them
and used for isotope infusions. A preinfusion sample was also underwent the renal vein catheterization. Hepatic
collected to measure basal isotope enrichments. Thereaf- blood flow was estimated by the continuous infusion
ter, primed-constant isotope infusions were started by technique, as described previously [11], using indocya-
means of calibrated pumps. The D5-phe and D2-tyr con- nine green dye (Becton Dickinson, Cockeysville, MD,
stant infusion rates were approximately 0.038 and ap- USA). Renal arterial plasma flow was calculated from
proximately 0.017 mmol/kg 3 min. The priming doses clearance and extraction of PAH using the Wolf equa-
were approximately 60 times the continuous infusion per tion [13]; therefore, it is referred to the two kidneys
minute. A priming dose of D4-tyr (0.4 mmol/kg) was also combined. True renal arterial blood flow (RBF) was
administered. After 120 minutes, a Teflon catheter was calculated by dividing plasma flow over (1 – hematocrit).
inserted percutaneously into a radial artery. Two intro-
Calculations and data presentationducer sets (8.5 F), distanced 1 cm from each other, were
placed into the femoral vein. A Cobra 7F catheter (Wil- Whole-body phenylalanine and tyrosine rates of ap-
liam Cook Europe, Bjaeverskov, Denmark) was then pearance (Ra) were calculated at steady state using es-
guided under fluoroscopic control through a femoral vein tablished formulas [5, 7]. Although not reported here,
achievement of the steady state in all the isotopic speciesto the right ventricular cavity or to a renal vein. After
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Table 1. Amino acid and isotope concentrations as well aswas effectively attained in the final hour of isotope infu-
phenylalanine and tyrosine kinetics
sion, as previously shown in a study of a duration similar
Kidney Splanchnic bedto that of this one [14], provided that the D4-tyrosine pool
1116692 1241 699is appropriately primed [5]. Whole-body phenylalanine
Renal Hepatichydroxylation to tyrosine (Phe Hy) was calculated using
Blood flow Artery vein Artery vein
an established equation [4, 5, 9, 10], as follows:
Concentrations
Phe 43.464.5 38.863.1a 40.664.8 35.764.0aPhe Hy
Tyr 47.364.7 51.264.7a 46.364.6 38.964.4a
Enrichments






(Eq. 1) D5-Phe 6.460.9 6.160.8a 6.560.8 4.960.7a
D4-Tyr 1.160.3 1.260.4 1.260.3 1.160.2
D2-Tyr 3.560.8 2.960.8a 3.860.7 3.060.6awhere Ra Tyr is the rate of appearance of tyrosine (in Isotope concentrations
mmol/min 3 kg); D4-tyr E and D5-phe E are mole per- D5-Phe 2.760.3 2.360.2a 2.660.3 1.760.2a
D4-Tyr 0.560.1 0.760.2a 0.560.1 0.460.1acentage enrichments of venous D4-tyrosine and D5-phe- D2-Tyr 1.660.3 1.460.3a 1.660.3 1.160.2anylalanine, respectively; Raphe is the rate of appearance Kinetics
of phenylalanine (in mmol/min 3 kg), and Infphe is the Phe Ra 1.43 60.81 10.1963.16
Phe Rd 6.9662.31b 16.3364.59brate of infusion of D5-phenylalanine (in mmol/min 3 kg). Hydroxylation 3.5160.97 2.48 61.35The venous D4-tyr and D5-phe enrichments were the Tyr Ra 9.75 61.20 7.25 61.25
average of the enrichments determined in the three ve- Tyr Rd 5.2562.20b 16.8862.17b
nous vessels. We used the venous rather than the arterial Organ blood flow (in ml/min 3 1.73 m2); phenylalanine (Phe); and tyrosine
(Tyr) concentrations (in nmol/ml), Mole Percent Enrichments; and isotope con-enrichments for whole-body hydroxylation measure-
centrations (in nmol/ml), in the artery, the renal, and the hepatic vein; Phe and
ments for the following reasons: (a) D4-tyrosine (from Tyr rates of appearance (Ra), disappearance (Rd), and Phe hydroxylation across
the organs (expressed in mmol/min 3 1.73 m2).D5-phenylalanine hydroxylation) is released into the a P , 0.05 or less vs. artery
vein. (b) Venous D5-phenylalanine enrichment is a better b P , 0.05 or less vs. Ra values
reflection than the arterial one of the enrichment in the
intracellular space, where hydroxylation takes place. Al-
though we did not directly measure intracellular enrich-
Phe Ra 5 Phe Rd 2 NB (Eq. 3)ments (which can be obtained only through biopsy), sam-
pling in the vein draining the region of interest may The same equations were used to calculate tyrosine
provide the closest, albeit indirect, estimate of intracellu- organ kinetics using the D2-tyr isotope data.lar enrichment. (c) The calculation of organ hydroxyla- Organ phenylalanine hydroxylation (Phe Hy) to tyro-
tion (discussed later in this article) [9, 10] is essentially sine was calculated as described previously [9, 10] as
based on the relative dilution in the vein of the D2-tyr follows:versus the D4-tyr tracers, using the venous enrichments
of D5-phe and D4-tyr as precursors and products of hy- organ Phe Hy
droxylation, respectively.











The rationale for this equation has been discussed inPhe Rd




3 100 3 flow 3 100021
Statistical analysis
(Eq. 2) Data were expressed as means 6 sem. The Student’s
t-tests for either unpaired or paired data were used aswhere D5-Pheart and D5-Pheven are D5-Phe isotope concen-
appropriate. A P value of less than 0.05 was consideredtrations (in nmol/ml) in the artery and the vein, respec-
statistically significant.tively. D5-Phe Eart is arterial D5-Phe enrichment. The
factor 100 is to correct for the percentage transformation
of enrichment (E); Flow is organ flow expressed as ml/
RESULTSmin 3 1.73 m2, and the factor 100021 is to convert nmol
In Table 1, amino acid and isotope concentrations andto mmol. Thus, the organ kinetic data were normalized
enrichments in the artery, the renal, and the hepatic vein,to 1.73 m2 of body surface.
as well as organ phenylalanine and tyrosine kinetics, areOrgan Phe net balance (NB) was calculated by sub-
reported. Phenylalanine concentration in the renal veintracting the venous from the arterial Phe concentration
was lower than that in the artery, resulting in a renal(in nmol/ml) and multiplying the difference times blood
flow. Phe Ra was then calculated as follows: net extraction of 4.63 6 2.22 mmol/min 3 1.73 m2. The
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Fig. 1. (A) Kidney, splanchnic, and whole body rates of phenylalanine hydroxylation to tyrosine. All data are expressed as mmol/min 3 1.73 m2.
Whole-body data are relative to the 6 subjects who underwent splanchnic catheterization (horizontal stripes) and relative to the 5 subjects who
underwent renal catheterization (the sum of the horizontal plus diagonal stripes on top). (B) Percent of either kidney or splanchnic phenylalanine
Rd accounted for by hydroxylation. *P , 0.001 vs. kidney data.
opposite was observed for tyrosine, in which the net DISCUSSION
release was 3.86 6 1.08 mmol/min 3 1.73 m2, that is, at Although the liver is classically considered the major
nearly equimolecular amounts of the phenylalanine net site of phenylalanine hydroxylation [2–5, 9], the hydrox-
extraction. Notably, the renal-vein D2-tyr enrichment ylating enzyme(s) also has been located in vitro in the
was lower than the arterial one (P , 0.01), whereas kidney [2]. In our study, we have simultaneously evalu-
the arterial and renal vein D4-tyr enrichments were not ated by means of organ catheterization and stable isotope
different. infusions the rates of renal and splanchnic phenylalanine
At the splanchnic bed level, the concentrations of both hydroxylation, as well as of organ phenylalanine and
phenylalanine and tyrosine in the hepatic vein were tyrosine uptake and release. Those data were compared
lower than those in the artery, indicating a net extraction with whole-body rates in postabsorptive humans.
of both amino acids (phenylalanine, 4.45 6 1.34 mmol/ This study demonstrates, to our knowledge for the
min 3 1.73 m2; tyrosine, 7.63 6 0.96 mmol/min 3 1.73 first time, a relevant phenylalanine hydroxylase activity
m2). The hepatic-vein D2-tyr enrichment was again lower within the human kidney.
than the arterial one (P , 0.01), whereas the arterial It is striking that the absolute rate of renal phenylala-
and hepatic-vein D4-tyr enrichments were not different. nine hydroxylation tended to be even greater (by approx-
Both organs simultaneously extracted and released imately 40%) than that occurring across the splanchnic
phenylalanine as well as tyrosine, although to a different area. If expressed per unit of organ mass (that is, 300 g
relative extent (Table 1). In the kidney, a relevant phe- for the kidneys, as compared with approximately 1000
nylalanine hydroxylation was detected, which tended to to 1500 g for the liver), kidney hydroxylation would be
be greater (by approximately 40%, P 5 NS) than that several-fold greater than that of the splanchnic area.
detected across the splanchnic area. The relative contri- Also, renal hydroxylation accounted for approximately
butions by each organ to whole-body hydroxylation are 70% of renal phenylalanine Rd, as opposed to only ap-
shown on Figure 1. The two organs together accounted proximately 8% across the splanchnic bed. Thus, hydrox-
for the entire whole-body phenylalanine hydroxylation ylation represents the major route of phenylalanine dis-
(kidneys, 69 6 15%; splanchnic bed, 51 6 27%). The posal within the kidney, as opposed to a minor fraction
sum of the two was not significantly different from 100%. within the splanchnic bed. From these calculations, only
Renal production of tyrosine from hydroxylation ac- 30% of renal phenylalanine Rd might be used for protein
counted for 12.8 6 4.2% of whole-body tyrosine Ra, synthesis. The two organs together accounted for ap-
whereas kidney total tyrosine Ra accounted for 33.6 6 proximately 100% of whole-body phenylalanine hydrox-
7.2% of whole-body tyrosine Ra. In the splanchnic bed, ylation, in agreement with the in vitro localization of
these figures were 8.6 6 4.4% and 39.7 6 11%, respec- phenylalanine hydroxylase almost exclusively found in
tively. More interestingly, renal hydroxylation accounted liver and kidney tissues [1–3].
for 71.2 6 31.9% of renal phenylalanine Rd, as opposed Among the two hydroxylating organs, another inter-
to 7.9 6 4.6% in the splanchnic area (P , 0.02 between esting comment concerns the fate of the tyrosine synthe-
sized de novo. Because there was a net release of tyrosinethe two organs; Fig. 1B).
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